Clinical Trials Directory

Trials / Terminated

TerminatedNCT01301963

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Comparison of Plerixafor and G-CSF Versus G-CSF Alone for Stem Cell Mobilization in Patients With Multiple Myeloma Previously Treated With Lenalidomide

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
9 (actual)
Sponsor
Case Comprehensive Cancer Center · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

This clinical trial studies filgrastim (G-CSF) with or without plerixafor in treating patients with multiple myeloma (MM) previously treated with lenalidomide. Giving colony-stimulating factors, such as G-CSF, and plerixafor helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored

Detailed description

PRIMARY OBJECTIVES: I. Ability to reach target collection of 5 x 10\^6 CD34+ cells/Kg with =\< 2 days of leukaphereses using one of two mobilization regimens. SECONDARY OBJECTIVES: I. Percentage of patients achieving target goal CD34+ cell dose (as above) in =\< 5 days of leukaphereses. II. Compare collections between different mobilization regimens in those patients who are crossed over from one mobilization regimen to the other. III. Compare days of apheresis, need for hospitalization during mobilization, and need for remobilization between mobilizing groups. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive G-CSF subcutaneously (SC) once daily (QD) on days 1-8. ARM II: Patients receive G-CSF SC QD on days 1-7 and plerixafor SC QD on days 4-7. After completion of study treatment, patients are followed up at 14 days.

Conditions

Interventions

TypeNameDescription
DRUGplerixaforGiven SC
BIOLOGICALfilgrastimGiven SC

Timeline

Start date
2011-07-01
Primary completion
2013-06-01
First posted
2011-02-23
Last updated
2014-08-06
Results posted
2014-08-06

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01301963. Inclusion in this directory is not an endorsement.